SynGenSys

SynGenSys Limited is a biotechnology firm that develops product-specific libraries of synthetic genetic components for use in next-generation biomedicines and biomanufacturing. Spun out of the University of Sheffield in 2021 by co-founders Professor David James (Chief Scientific Officer) and Dr. Adam Brown (Chief Technology Officer), the company leverages proprietary technology rooted in years of academic and bio-industrial research. The firm's core platform uses bioinformatic analysis of large-scale biological data to engineer and construct novel synthetic genetic parts tailored to specific products or processes, aiming to enhance the design and production of biopharmaceuticals and gene therapies.

Based in Sheffield, United Kingdom, SynGenSys operates at the intersection of cell biology, molecular biology, informatics, and engineering. The company's business model focuses on providing its specialized products and services to a global customer base in the biotechnology and pharmaceutical sectors. Its technology enables clients to design and manufacture new biomolecules with desired characteristics.

The company has secured significant early-stage funding to support its growth and commercialization efforts. In April 2024, SynGenSys announced an angel-led seed fundraise of £1.8 million (approximately $2.26 million). This funding is intended to expand its product offerings and services to a worldwide market. Takeda Ventures is listed as an investor in the company.

Keywords: synthetic biology, biomanufacturing, genetic engineering, biomedicine, gene therapy, synthetic promoters, cell engineering, CHO cells, biopharmaceuticals, drug discovery, molecular biology, bioinformatics, cell line development, recombinant proteins, genetic components, biotechnology research, DNA design, bioprocesses, biologics production, therapeutic genes.